AU
UK
CA
NZ
IND
US
Analysts suggest investing in Phreesia Inc. (NYSE: PHR) post the release of its financial results for Q1 2024. For the three months ended April 30, 2023, Phreesia reported a total revenue of US$ 83.8 million. The mean recommendation for PHR is 1.6 on a …
PVH Corp. (NYSE: PVH) reported a first quarter revenue of US$ 2.158 billion, higher than the company expectations of no major change over the prior year period. After the announcement, PVH received a rating upgrade from Wells Fargo Securities.
Capital Southwest, a financing solutions provider, released its results for Q4 FY23 ended March 31, 2023. The financial results were released on May 24, 2023, highlighting the company’s total investment portfolio of US$ 1.2 billion.
Diana Shipping released its financial results for the three months ended March 31, 2023, reporting a net income of US$ 22.7 million in the quarter. The announcement resulted in Artic Securities upgrading its rating to ‘Buy’ on DSX.
AutoZone, a premier seller of automotive parts and accessories, has received a ‘Buy’ rating from analysts post the release of its Q3 financial results. For the three months ended May 6, 2023, AutoZone reported 5.8% sequential increase in net sales to US$ 4.1 billion.
Onconova is a biopharmaceutical company centered towards developing and uncovering products that treat cancer. One of the latest developments for the company has been the initiation of the dosing in its treatment drug for endometrioid endometrial cancer Onconova also announced that the first participant …
Onconova is a biopharmaceutical company centered towards developing and uncovering products that treat cancer. One of the latest developments for the company has been the initiation of the dosing in its treatment drug for endometrioid endometrial cancer Onconova also announced that the first participant …
Brokers revised their ratings on Fabrinet after the release of the company’s financial results for Q3 FY23. Fabrinet announced that its results for the quarter ended March 31, 2023, exceeded its guidance.
As Disc Medicine reported a bump in its cash position during Q1 2023, brokers retained their “Buy” recommendations on the stock.
Perion received upgraded broker recommendations after the release of its financial results for Q1 2023. The company’s results highlighted its performance in the adtech industry across its three primary channels of digital advertising.
Please wait processing your request...